123 related articles for article (PubMed ID: 9864558)
1. [Management of atherogenic hyperlipidemia].
Turpin G; Bruckert E
Ann Cardiol Angeiol (Paris); 1998 Nov; 47(9):627-32. PubMed ID: 9864558
[TBL] [Abstract][Full Text] [Related]
2. Management of hypercholesterolaemia in the patient with diabetes.
Packard C; Olsson AG
Int J Clin Pract Suppl; 2002 Jul; (130):27-32. PubMed ID: 12296606
[TBL] [Abstract][Full Text] [Related]
3. [Lipid-lowering therapy in patients with type-2 diabetes mellitus].
Pados G; Audikovszky M
Orv Hetil; 2003 Mar; 144(12):557-61. PubMed ID: 12723526
[TBL] [Abstract][Full Text] [Related]
4. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
[TBL] [Abstract][Full Text] [Related]
5. Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.
Kłosiewicz-Latoszek L; Szostak WB; Grzybowska B; Białobrzeska-Paluszkiewicz J; Wiśniewska B; Stolarska I
Kardiol Pol; 2004 Jun; 60(6):567-77. PubMed ID: 15334157
[TBL] [Abstract][Full Text] [Related]
6. Switching fibrate to statin in type 2 diabetic patients: consequences on lipid profile.
Meas T; Laloi-Michelin M; Virally M; Peynet J; Giraudeaux V; Kévorkian JP; Guillausseau PJ
Eur J Intern Med; 2009 Mar; 20(2):197-200. PubMed ID: 19327612
[TBL] [Abstract][Full Text] [Related]
7. [Hypertriglyceridemia--diagnostics, risk and treatment].
Hexeberg S; Retterstøl K
Tidsskr Nor Laegeforen; 2004 Nov; 124(21):2746-9. PubMed ID: 15534665
[TBL] [Abstract][Full Text] [Related]
8. Analysis of serum lipids and lipoproteins in Ethiopian diabetic patients.
Seyoum B; Abdulkadir J; Berhanu P; Feleke Y; Mengistu Z; Worku Y; Ayana G
Ethiop Med J; 2003 Jan; 41(1):1-8. PubMed ID: 12764995
[TBL] [Abstract][Full Text] [Related]
9. [Lipid risk factors of atherosclerosis: who, when, how to treat?].
Foubert L; Dejager S; Bruckert E; Turpin G
Ann Endocrinol (Paris); 1997; 58(4):275-82. PubMed ID: 9436473
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of rosuvastatin in low-density lipoprotein cholesterol lowering and National Cholesterol Education Program Adult Treatment Panel guideline III LDL-C goal attainment compared to other statins among diabetes mellitus patients: a retrospective study using an electronic medical records dataset in the United States.
Fox KM; Gandhi SK; Ohsfeldt RL; Blasetto JW; Bays HE
Curr Med Res Opin; 2007 Sep; 23(9):2125-33. PubMed ID: 17655813
[TBL] [Abstract][Full Text] [Related]
11. Hyperlipidemia in children with type 2 diabetes mellitus.
Taha D
J Pediatr Endocrinol Metab; 2002 Apr; 15 Suppl 1():505-7. PubMed ID: 12017224
[TBL] [Abstract][Full Text] [Related]
12. The lipid triad in type 2 diabetes - prevalence and relevance of hypertriglyceridaemia/low high-density lipoprotein syndrome in type 2 diabetes.
Temelkova-Kurktschiev T; Hanefeld M
Exp Clin Endocrinol Diabetes; 2004 Feb; 112(2):75-9. PubMed ID: 15031770
[TBL] [Abstract][Full Text] [Related]
13. Effects of soybean D-LeciVita product on serum lipids and fatty acid composition in type 2 diabetic patients with hyperlipidemia.
Ristić Medić D; Ristić V; Arsić A; Postić M; Ristić G; Blazencić Mladenović V; Tepsić J
Nutr Metab Cardiovasc Dis; 2006 Sep; 16(6):395-404. PubMed ID: 16935698
[TBL] [Abstract][Full Text] [Related]
14. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin.
Breuer HW
Curr Med Res Opin; 2001; 17(1):60-73. PubMed ID: 11464448
[TBL] [Abstract][Full Text] [Related]
15. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia.
Guyton JR; Brown BG; Fazio S; Polis A; Tomassini JE; Tershakovec AM
J Am Coll Cardiol; 2008 Apr; 51(16):1564-72. PubMed ID: 18420099
[TBL] [Abstract][Full Text] [Related]
16. Statins and diabetes.
Carmena R; Betteridge DJ
Semin Vasc Med; 2004 Nov; 4(4):321-32. PubMed ID: 15861314
[TBL] [Abstract][Full Text] [Related]
17. Statins and omega-3 fatty acids in the treatment of dyslipidemia and coronary heart disease.
Nordøy A
Minerva Med; 2002 Oct; 93(5):357-63. PubMed ID: 12410168
[TBL] [Abstract][Full Text] [Related]
18. The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.
Christidis DS; Liberopoulos EN; Kakafika AI; Miltiadous GA; Cariolou M; Ganotakis ES; Mikhailidis DP; Elisaf MS
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):211-21. PubMed ID: 17056835
[TBL] [Abstract][Full Text] [Related]
19. [Long-term results of the use of different modifications of the partial ileal shunt operation in the treatment of patients with atherogenic dyslipoproteinemias].
Mirchuk KK; Lebedev LV; Sedletskiĭ IuI
Vestn Khir Im I I Grek; 2001; 160(1):29-32. PubMed ID: 11258320
[TBL] [Abstract][Full Text] [Related]
20. The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.
Saklamaz A; Comlekci A; Temiz A; Caliskan S; Ceylan C; Alacacioglu A; Yesil S
Metabolism; 2005 May; 54(5):677-81. PubMed ID: 15877299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
